TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Skin improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: overall risk of developing grade 3 ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: TUNEL levels at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of supine systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in potassium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pain score during removal of inner layer dressing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival rate of microskin autografts
Endpoint domain: Mortality/survival
Primary endpoint: Walking test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of combination therapy for nocturnal enuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily step counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial cell density (EC density)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from treatment failure (FFTF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit to stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: supervision knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: frequency of proactive safety behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychic anxiety improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight percentiles decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol to HDL ratio decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target limb salvage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ankle-brachial index (ABI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bone Mineral Density (BMD) at the femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Total recovery rate after treatment
Endpoint domain: Mortality/survival
Primary endpoint: Hearing improvement at 250 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration in Barthel score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IADL score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumbar function improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Partial responses in tumor shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Receipt of life skills instruction/training
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: percentage of hyponatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of problem-solving coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sense of personal control
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Amylase activity in the duodenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Five-year PCa-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: virologic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate (HR) during orthostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Arterial Pressure (MAP) after ACE inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of NSAID associated peptic ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dyspeptic symptoms requiring therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Loss to follow-up rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: INH-DILI incidence
Endpoint domain: Adverse events/effects
Primary endpoint: early treatment failure incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Cord-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of Mucociliary Transport time (MCTt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreasing of nasal resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure less than or equal to 18 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Attention and Executive Function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of injections received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: non-fatal major cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of optimal insertion conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: whole blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit in heart failure patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amenorrhoea achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of menopausal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Errors in crossing at posttest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of spontaneous labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: etiological determination of acute pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: escaping victimization
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative pain medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of subjective tinnitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PM length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pyrophosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Serum total calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Low % predicted OUEP as a predictor of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in facial skin texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in full‐face telangiectasias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in dermal collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Grade ≥3 hematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Complete reporting of CONSORT items
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of written English
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median time of overall acceptance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Testing behaviour
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of urinary excretion of 4‐carboxypyrazole (4‐CP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Asthma Control Questionnaire (ACQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Radiographic evidence of solid arthrodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinically successful outcomes (20% improvement in Oswestry scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GFR values agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crohn's disease activity index discrimination ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total exercise confidence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Running confidence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bifidobacteria growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of movement and sympathetic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of stitches placed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subjective feeling of understanding and mastering
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiac output difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Large bowel transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of deoxycholic acid in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Meaningful improvement in Kansas City Cardiomyopathy Questionnaire overall summary score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete absence of sensation to pinprick at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite score of digestive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Instant analgesic effect rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise VO(2) tau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product preference shifts
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patent ductus arteriosus closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 h postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall time of colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to reach the cecal floor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Photodamage grade reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriateness of nephrologist referrals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety improvement
Endpoint domain: Adverse events/effects
Primary endpoint: Serum AST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Score of peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensory nerve conduction velocity (SNCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor nerve conduction velocity (MNCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of temporary ileus
Endpoint domain: Adverse events/effects
Primary endpoint: Change in wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak head velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of microleakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary graft patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Secondary graft patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical and hemodynamic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PEG tube dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ropy mucous discharge, photophobia, conjunctival hyperemia, and limbal edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for medication during posttreatment follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: reducing exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reducing morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour response rate (TRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lowering the extent of HIV RNA rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-reported poor sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Physical health status (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental health status (MCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: WOMAC physical function subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adenoma risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: multiple adenoma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response to methimazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Euthyroid status within 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-hour blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients receiving homologous blood within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients receiving homologous blood within 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Academic performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: learning outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 30-day ppa
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in left ventricular end-diastolic volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in left atrial volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motor and sensory block development time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic insulin extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peripheral insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnostic accuracy of tru-cut core biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best overall response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healed ulcer
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: reduced pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTV stability over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Response rate to adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite unfavorable endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Diabetes Treatment Satisfaction (DTSQ Q1 + Q4-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-management improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: deterioration in health (ADL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac death or hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and severity of anxiety disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term pain complaints
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: improved patient outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma bupivacaine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement for oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean post-randomization HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of lower extremity amputation (LEA)
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in papulopustular lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rosacea severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in cognitive scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual distress relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sleep time (hours)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percent of subjects using opioids posttreatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sexual Problem Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual Activities Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in plasma HIV RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time difference between arch changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor scars
Endpoint domain: Adverse events/effects
Primary endpoint: amount of analgesics intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modality use per week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Likert survey of cold intolerance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pancreatic β‐cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Parent-reported posttraumatic stress symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child-reported anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child-reported depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of follicular rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Delay of ovulation for at least 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: F(E)NO concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of unfavourable outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative malreduction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate/severe HAH incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial estradiol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean abstinence duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of target NAPSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal higher-order wavefront aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep breathing ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recovery of daily physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes